What is Voyager Therapeutics Book Value per Share?
Voyager Therapeutics's book value per share for the quarter that ended in Mar. 2024 was €5.77.
During the past 12 months, Voyager Therapeutics's average Book Value Per Share Growth Rate was 25.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Voyager Therapeutics was 20.40% per year. The lowest was -40.40% per year. And the median was -9.10% per year.
During the past 11 years, the highest P/B Ratio of Voyager Therapeutics was 13.70. The lowest was 0.98. And the median was 2.57.
Good Sign:
Voyager Therapeutics Inc stock PB Ratio (=1.29) is close to 2-year low of 1.2
Voyager Therapeutics Book Value per Share Historical Data
The historical data trend for Voyager Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Voyager Therapeutics's Book Value per Share
For the Biotechnology subindustry, Voyager Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyager Therapeutics's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Voyager Therapeutics's PB Ratio falls into.
Voyager Therapeutics Book Value per Share Calculation
Voyager Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Voyager Therapeutics (STU:VT6) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Voyager Therapeutics Book Value per Share Related Terms
Thank you for viewing the detailed overview of Voyager Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Voyager Therapeutics (STU:VT6) Business Description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:VT6 has been successfully added to your 